767 related articles for article (PubMed ID: 11559718)
1. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
2. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
8. Letrozole in the neoadjuvant setting: the P024 trial.
Ellis MJ; Ma C
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
[TBL] [Abstract][Full Text] [Related]
9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
10. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M;
Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750
[TBL] [Abstract][Full Text] [Related]
11. Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria?
Pritchard KI
J Clin Oncol; 2001 Sep; 19(18):3795-7. PubMed ID: 11559715
[No Abstract] [Full Text] [Related]
12. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
14. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
15. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Smith IE
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
[TBL] [Abstract][Full Text] [Related]
16. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
[TBL] [Abstract][Full Text] [Related]
18. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
